| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ATRA | ATRA | Shares | USD | XNGS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ATRA | ATRA | Shares | USD | XNGS |
Atara Biotherapeutics, Inc. develops cell-based immunotherapies using its Epstein-Barr virus (EBV) T-cell platform. The company focuses on allogeneic (donor-derived) T cells and next-generation CAR T technologies to target and eliminate disease-causing cells. Atara's products aim to address cancer and autoimmune diseases, serving patients globally through its advanced manufacturing capabilities.
No recent RNS announcements for ATRA across ATRA.
No recent RNS announcements for ATRA across ATRA.